Researchers at Université Laval in Quebec have demonstrated for the first time that omega-3 polyunsaturated fatty acids (PUFA) confer a protective benefit against the development of Parkinson’s disease. The finding was reported online on November 21, 2007 in the Journal of the Federation of American Societies for Experimental Biology ( FASEB).
Frédéric Calon, of Laval’s center for research in molecular and oncologic endocrinology, and his associates fed mice a diet enriched with the omega-3 fatty acids eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and linolenic acid, or a control diet deficient in these fatty acids. After ten months on the diets, the animals were injected over a five day period with an inert substance or MPTP, a neurotoxin that damages the brain in a manner similar to Parkinson’s disease. “This compound, which has been used for more than 20 years in Parkinson’s research, works faster than the disease itself and is just as effective in targeting and destroying the dopamine-producing neurons in the brain,” Dr Calon explained.
Two weeks following the administration of MPTP, examination of the animals’ brains revealed an increase in frontal cortex levels of DHA and a decline in the omega-6 fatty acid DPA in those that received the omega-3 fatty acid rich diet. In mice that received the control diet, treatment with MPTP resulted in a 31 percent reduction in the substantia nigra’s dopaminergic neurons, which are progressively destroyed in humans with Parkinson’s disease. This effect was prevented in mice that received high amounts of omega-3 fatty acids. Omega-3 fatty acids also appeared to help protect against the decrease in dopamine transporter levels observed in MPTP-treated mice that received the control diets. (Dopamine is a neurotransmitter produced by dopaminergic cells, and is involved with movement control.)
Because the brains of the omega-3 group did not show significant changes in arachidonic acid, linolenic acid, or EPA levels, the authors suggest that DHA is the primary omega-3 fatty acid involved in the protective effect demonstrated in this study, or, alternately, that the relatively high omega-6 fatty acid content of the control diet may increase the risk of Parkinson’s disease.
“In North America, the average intake of DHA is between 60 to 80 mg a day, while experts recommend a daily minimum of 250 mg,” Dr Calon observed. “Our results suggest that this DHA deficiency is a risk factor for developing Parkinson’s disease, and that we would benefit from evaluating omega-3’s potential for preventing and treating this disease in humans.”
“As our present results suggest, this prevalent low consumption of DHA might be an important modifiable risk factor for Parkinson’s disease,” the authors conclude. “Fortunately, it is easy to treat omega-3 PUFA deficiency by changes in dietary habits or by administration of inexpensive supplements. Indeed, omega-3 PUFA are nonpatentable, widely available at low cost, and have an excellent safety profile.”